公开(公告)号：EP4355724A1

公开(公告)日：2024-04-24

申请号：EP22734296.1

申请日：2022-06-16

Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

Inventor： GLÖGGLER, Stefan ,  KORCHAK, Sergey ,  JATAP, Anil P. ,  SAUL, Philip ,  MOLL, Denis

IPC: C07C69/68 ,  C07C67/307 ,  C07C67/31 ,  C07C271/22 ,  C07C201/12 ,  C07C205/34 ,  C07B59/00

CPC classification number: C07C271/22 ,  C07C67/307 ,  C07C67/31 ,  C07C69/68 ,  C07B2200/0520130101 ,  C07B59/001 ,  C07C201/12

公开(公告)号：EP3380447A1

公开(公告)日：2018-10-03

申请号：EP16801234.2

申请日：2016-11-24

Applicant: Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Centre National de la Recherche Scientifique ,  Universite de Nantes ,  Université d'Angers ,  The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services

Inventor： GUERARD, François ,  GESTIN, Jean-François ,  BRECHBIEL, Martin W ,  LEE, Yong-Sok

IPC: C07B59/00 ,  C07D207/46 ,  C07C17/361 ,  C07C25/24 ,  C07C67/307 ,  C07C41/18 ,  C07C201/12 ,  C07C247/10 ,  C07C247/16 ,  C07C253/30

CPC classification number: C07C25/24 ,  C07B59/001 ,  C07B59/002 ,  C07B59/008 ,  C07B2200/05 ,  C07C17/361 ,  C07C29/10 ,  C07C29/58 ,  C07C29/62 ,  C07C33/46 ,  C07C41/18 ,  C07C43/225 ,  C07C67/307 ,  C07C201/12 ,  C07C247/10 ,  C07C247/16 ,  C07C253/30 ,  C07D207/46 ,  C07C69/76 ,  C07C255/50 ,  C07C205/11

Abstract: The present invention concerns a method of synthesizing a iodo- or astatoarene comprising the reaction of a diaryliodonium compound with a iodide or astatide salt, respectively. The invention also relates to said iodo- or astatoarene and diaryliodonium compound as such. The invention also concerns a method of synthesizing a iodo- or astatolabelled biomolecule and/or vector using said iodo- or astatoarene.

公开(公告)号：EP3004049B1

公开(公告)日：2018-09-05

申请号：EP14725542.6

申请日：2014-02-12

Applicant: Cellixbio Private Limited

Inventor： KANDULA, Mahesh

IPC: C07C229/22 ,  C07D213/80 ,  C07D213/82 ,  C07D233/64 ,  C07D339/04 ,  C07C235/12 ,  A61P3/10 ,  C07C279/26 ,  C07C55/10 ,  C07C57/03 ,  C07C59/347

CPC classification number: C07C235/12 ,  A61K31/155 ,  A61K31/202 ,  A61K31/23 ,  C07B59/001 ,  C07C55/10 ,  C07C57/03 ,  C07C57/145 ,  C07C59/347 ,  C07C229/22 ,  C07C229/24 ,  C07C235/60 ,  C07C279/26 ,  C07C279/265 ,  C07D213/80 ,  C07D213/82 ,  C07D233/64 ,  C07D339/04

Abstract: The invention relates to the compositions of formula I or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of metformin and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.

公开(公告)号：EP3215147A4

公开(公告)日：2018-05-30

申请号：EP15856205

申请日：2015-11-04

Applicant: AMORSA THERAPEUTICS INC

Inventor： NIVOROZHKIN ALEX ,  LANDRAU NELSON

IPC: A61K31/215 ,  C07C225/20

CPC classification number: C07C225/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K31/135 ,  A61K45/06 ,  C07B59/001 ,  C07B2200/05 ,  C07C2601/14 ,  A61K2300/00

Abstract: The present invention is directed to novel neuro-attentuating norketamine (NANKET) compounds according to any one of formulas (I - shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.

公开(公告)号：EP2106808B1

公开(公告)日：2018-02-21

申请号：EP07832174.2

申请日：2007-11-20

Applicant: Nihon Medi-Physics Co., Ltd.

Inventor： HAYASHI, Akio ,  SHINMURA, Toshiyuki ,  NAKAMURA, Daisaku ,  NAKAMURA, Soichi ,  TOKUNAGA, Shinji ,  KANEKO, Emi ,  TOYAMA, Masahito

IPC: A61K51/04 ,  A61K101/02 ,  C07B59/00 ,  A61K49/00 ,  A61K9/08

CPC classification number: A61K49/0433 ,  A61K47/26 ,  A61K51/04 ,  A61K51/0406 ,  C07B59/001

Abstract: A composition comprising a radioactive fluorine-labeled amino acid compound is provided, which can be prevented from radiolysis. Disclosed is a composition which comprises a solution containing a radioactive fluorine-labeled amino acid compound as an effective ingredient, in which the pH value of the solution is kept at 2.0-5.9, more preferably 2.0-4.9 in order to inhibit radiolysis. Also, it is possible to further inhibit radiolysis by adding thereto a pharmaceutical additive capable of inhibiting radiolysis, such as a sugar, a sugar alcohol and a sugar lactone, whilst the pH is kept at 2.0-5.9.

公开(公告)号：EP2746250B1

公开(公告)日：2017-09-27

申请号：EP12199109.5

申请日：2012-12-21

Applicant: ABX Advanced Biochemical Compounds GmbH

Inventor： Hoepping, Alexander ,  Müller, Marco ,  Smits, René ,  Mollitor, Jan ,  Clausnitzer, Andreas ,  Baumgart, Diana

IPC: C07C227/16 ,  C07C229/36 ,  C07B59/00

CPC classification number: C07B59/001 ,  C07B2200/05 ,  C07C227/16 ,  C07C229/36

公开(公告)号：EP3160923A1

公开(公告)日：2017-05-03

申请号：EP15732267.8

申请日：2015-06-30

Applicant: GE Healthcare Limited

Inventor： DYRSTAD, Knut Richard ,  WICKSTROM, Torild ,  RAJANAYAGAM, Thanushan

IPC: C07B59/00

CPC classification number: A61K51/0402 ,  C07B59/001 ,  C07B2200/05 ,  C07C227/20 ,  C07C2601/04

Abstract: The present invention provides a composition comprising anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid (18F-FACBC) having an improved impurity profile compared with previous such compositions. Also provided is a method to obtain said composition.

Abstract translation: 本发明提供了一种组合物，其包含与先前的这种组合物相比具有改进的杂质分布的抗1-氨基-3-18F-氟代环丁基-1-羧酸（18F-FACBC）。 还提供了获得所述组合物的方法。

公开(公告)号：EP3134421A1

公开(公告)日：2017-03-01

申请号：EP15720662.4

申请日：2015-04-24

Applicant: Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Centre Hospitalier Universitaire de Montpellier ,  Université d'Auvergne ,  Université de Montpellier

Inventor： BRABET, Philippe ,  CIA, David ,  GUILLOU, Laurent ,  HAMEL, Christian ,  VIGOR, Claire ,  DURAND, Thierry ,  CRAUSTE, Céline ,  VERCAUTEREN, Joseph

IPC: C07F9/10 ,  C07C69/24 ,  C07C69/58 ,  C07C69/587 ,  A61K31/661 ,  A61K31/23 ,  A61K31/232 ,  A61P29/00 ,  A61P35/00 ,  A61P3/00

CPC classification number: C07F9/10 ,  C07B59/001 ,  C07B59/004 ,  C07B2200/05 ,  C07C69/017 ,  C07C69/587 ,  C07F9/106

Abstract: The present invention relates to a compound of formula (I) wherein: - i is 0 or 1; j is 0 or 1; k is 0 or 1; - R1 and R2 are in particular H, (C1-C12)alkyl, or a group of formula C(O)R; - R is a, linear or branched, alkyl radical, comprising at least 19 carbon atoms; - R3 is H and k=0 when j=1; or, when j=0, R3 is -C(O)R or -L-C(O)R; - L, U and L" are linkers; wherein, when j=0, at least one of the groups R1; R2 and R3 comprises a radical R.

Abstract translation: 本发明涉及式（I）的化合物，其中：-i是0或1; j是0或1; k是0或1; -R 1和R 2特别是H，（C 1 -C 12）烷基或式C（O）R的基团; -R是直链或支链烷基，包含至少19个碳原子; - 当j = 1时，R3是H并且k = 0; 或者当j = 0时，R 3是-C（O）R或-L-C（O）R; -L，U和L“是连接体;其中当j = 0时，基团R 1，R 2和R 3中的至少一个包含基团R.

公开(公告)号：EP3083526A1

公开(公告)日：2016-10-26

申请号：EP14815726.6

申请日：2014-12-18

Applicant: GE Healthcare Limited

Inventor： ENGELL, Torgrim ,  MEIJER, Andreas, Richard ,  KHAN, Imitiaz Ahmed ,  NAIRNE, Robert James ,  MCROBBIE, Graeme

IPC: C07B59/00 ,  C07B63/00

CPC classification number: A61K51/088 ,  A61K51/04 ,  A61K51/121 ,  B01D15/20 ,  B01D15/22 ,  B01D15/325 ,  B01D15/426 ,  C07B59/00 ,  C07B59/001 ,  C07B63/00 ,  C07B2200/05 ,  C07K1/13 ,  C07K1/145 ,  C07K14/001

Abstract: The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to a method of purifying a radiotracer which comprises 18F-labelled aminoxy-functionalised biological targeting moiety. The invention provides radioprotectant-containing radiopharmaceutical compositions of the tracers, as well as associated automated methods and cassettes.

公开(公告)号：EP2933246A4

公开(公告)日：2016-09-07

申请号：EP13862184

申请日：2013-12-09

Applicant: ENDOTHERM GMBH

Inventor： LÓPEZ PÉREZ BORJA ,  SIGÜEIRO PONTE RITA ,  MAESTRO SAAVEDRA MIGUEL A ,  MOURIÑO MOSQUERA ANTONIO

IPC: C07C401/00 ,  A61K31/593 ,  A61K51/04 ,  C07B59/00 ,  C07C49/443 ,  C07C49/633 ,  C07C67/313 ,  C07F7/18

CPC classification number: C07C49/633 ,  A61K51/0493 ,  C07B59/001 ,  C07C49/443 ,  C07C67/313 ,  C07C401/00 ,  C07C2601/14 ,  C07C2602/24 ,  C07F7/1804 ,  C07F7/1852 ,  C07F7/1872

Abstract: Versatile and functionalised intermediates for the synthesis of vitamin D and novel vitamin D derivatives. The invention provides novel intermediates for the complete synthesis of vitamin D and allows a great versatility of functional groups in the final vitamin derivatives. The invention also provides vitamin derivatives that are epimeric in position 3 and vitamin derivatives with a wide range of functionalities in position 18, including compounds with isotopic labeling

Abstract translation: 多功能和官能化的中间体，用于维生素D和维生素D衍生物新颖的合成。 本发明提供了维生素D的全合成的新的中间体和允许官能团在最终维生素衍生物一个很大的通用性。 因此本发明提供维生素衍生物并在适当的位置3和维生素衍生物差向异构体与在位置18上的广泛的功能，包括与同位素标记的化合物